Difficulty: Medium
Average Score: 83%
Testbank
Which of the following is an outcome of the drug memantine (Namenda) in clients with advanced stages of Alzheimer disease?
Correct answer
C
Rationale
C: Lessens symptoms.
Memantine (Namenda) is used to manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity, which helps in reducing cognitive decline and improving overall functioning in clients. This outcome is particularly relevant in advanced stages where symptom management is crucial for maintaining quality of life.
A: Less depression.
While memantine may have some influence on mood, its primary action is not aimed at treating depression specifically, making this option less relevant to the symptom management of advanced Alzheimer's disease.
B: Increased brain excitability.
Memantine actually works to decrease excessive excitability in the brain by blocking NMDA receptors, which helps in alleviating symptoms rather than increasing excitability, thus making this choice inappropriate.
D: Decreased brain excitability.
Although memantine does decrease excitability, this option does not directly address the broader outcome of lessening symptoms, which is the primary focus of the question regarding advanced Alzheimer's disease management.
Memantine (Namenda) is used to manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity, which helps in reducing cognitive decline and improving overall functioning in clients. This outcome is particularly relevant in advanced stages where symptom management is crucial for maintaining quality of life.
A: Less depression.
While memantine may have some influence on mood, its primary action is not aimed at treating depression specifically, making this option less relevant to the symptom management of advanced Alzheimer's disease.
B: Increased brain excitability.
Memantine actually works to decrease excessive excitability in the brain by blocking NMDA receptors, which helps in alleviating symptoms rather than increasing excitability, thus making this choice inappropriate.
D: Decreased brain excitability.
Although memantine does decrease excitability, this option does not directly address the broader outcome of lessening symptoms, which is the primary focus of the question regarding advanced Alzheimer's disease management.